Evidence map›Paper›PMID 29780751›Full record

ArticleAutopsy & case reports

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis.

Joana Simões, Isabel Augusto, Sara Meireles, Lurdes Vendeira, Carlos Silva

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Autopsy & case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joana SimõesUniversity of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal .
Isabel AugustoUniversity of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal .
Sara MeirelesUniversity of Porto, Centro Hospitalar de São João, Department of Oncology . Porto , Portugal .
Lurdes VendeiraUniversity of Porto, Centro Hospitalar de São João, Department of Urology . Porto , Portugal .
Carlos SilvaUniversity of Porto, Centro Hospitalar de São João, Department of Radiation Oncology . Porto , Portugal .
Hospital de São João · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.

Indexed as

DialysisDocetaxelEnzalutamideProstate cancerRadium-223

Identifiers

PMID29780751
PMCPMC5953181
OpenAlexW2789246146

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.